You are here

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
Antiretroviral pre-exposure prophylaxis for HIV prevention is highly effective in community settings
  1. Angela Robertson Bazzi
  1. Boston University School of Public Health, Boston, Massachusetts, USA
  1. Correspondence to : Professor Angela Robertson Bazzi, Boston University School of Public Health, 801 Massachusetts Ave, 442E, Boston, MA 02118, USA; abazzi{at}bu.edu

https://doi.org/10.1136/ebmed-2016-110403

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016;387:53–60.OpenUrlCrossRefPubMed

    Context

    Randomised placebo-controlled trials have demonstrated the efficacy of antiretroviral pre-exposure prophylaxis (PrEP) in preventing HIV-1 acquisition in diverse international populations including men who have sex with men (MSM).1–3 However, concerns regarding adherence to daily regimens and potential risk compensation (eg, increased engagement in condomless sex) in real-world settings have contributed to skepticism and delayed implementation of PrEP. The PROUD open-label randomised pilot trial tested the effectiveness of daily oral PrEP delivered to high-risk MSM through 13 sexual health …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.